GLP-1
| 4 min read
Eli Lilly’s oral orforglipron and Novo Nordisk’s higher-dose WeGovy could be approved on an extremely accelerated timeline.
| 3 min read
Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease.
| 5 min read
Explore the mechanisms, clinical applications, and future opportunities of GLP-1 receptor agonists in drug development and disease management.
| 4 min read
Positive results for breast cancer, funding for precision therapies for heart disease, strong results for Lilly’s oral GLP-1, and more led the news this week.
| 7 min read
With blockbuster status secured, GLP-1 therapies face new questions about efficacy, delivery, and their role in treating multiple chronic diseases.
| 2 min read
Researchers showed that in rodent models, a glia-produced molecule could regulate weight loss and glucose metabolism without gastrointestinal symptoms.
| 4 min read
Explore the link between GLP-1 drugs and cancer. A new study reveals these therapies may reduce the risk of obesity-related cancers, similar to bariatric surgery.
| 5 min read
Promising small cell lung cancer results, COVID-19 vaccine confusion, billion-dollar deals, and more led the news this week.
| 5 min read
From an executive order to lower drug prices to GLP-1 drug comparisons and a link between Parkinson’s disease and golf courses, it was a busy industry news week.
| 5 min read
Insights from the AD/PD meeting, continued fallout from the FDA layoffs, hope for GLP-1 drugs in Alzheimer’s disease, and more led industry news this week.
